Bizarre Patents
A coffin, for allowing inclination for display of a deceased person in a natural position.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173127 | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof The invention relates to methods of treating a subject having Alzheimer's Disease, comprising the step of administering an antibody molecule which is targeted to β amyloid peptide or to fragment thereof. In another embodiment the invention relates to methods of tre... | 05/08/2012 |
| 8105594 | Methods for amyloid removal using anti-amyloid antibodies Methods and related immunoglobulin peptides and fragments thereof are disclosed that enhance the cell-mediated immune response of a patient to deposits of amyloid fibrils. These methods exploit the opsonizing effect of antibodies directed toward amyloid material or ... | 01/31/2012 |
| 8003100 | Antibodies that bind to 238P1B2 A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a ... | 08/23/2011 |
| 7846439 | Domain antibody construct The present invention provides a domain antibody construct which binds to human TNF-α, with the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-α; (b) a modified hinge region sequence; | 12/07/2010 |
| 7833527 | Methods of treating psoriasis using IL-17 Receptor A antibodies The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation. ... | 11/16/2010 |
| 7744879 | Blood-brain barrier targeting antibodies This invention provides antibodies that bind brain endothelial cell receptors resulting in endocytosis/transcytosis of the receptor and bound ligands. In some embodiments, the ligand comprises the antibody in combination with a pharmaceutically active compound and t... | 06/29/2010 |
| 7722869 | Antibody molecules and nucleic acids An scFv peptide comprising a VH domain and a VL domain linked by an amino acid spacer is disclosed. The VH domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 64. The VL domain com... | 05/25/2010 |
| 7632501 | Antibodies against monocyte chemotactic proteins The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same. ... | 12/15/2009 |
| 7615218 | Methods for determining and lowering caffeine concentration in fluids Single-chain, camelized heavy chain antibodies immunospecific for caffeine and stable at high temperatures are useful for analysis and recovery of caffeine in or from fluids. A device that provides a single-step lateral flow assay for caffeine and a useful peptide s... | 11/10/2009 |
| 7579000 | Tissue factor targeted antibodies as anticoagulants This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the s... | 08/25/2009 |
| 7438905 | Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositi... | 10/21/2008 |
| 7435412 | Chronic lymphocytic leukemia cell line The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are usefu... | 10/14/2008 |
| 7435799 | TNF-α binding molecules The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation... | 10/14/2008 |
| 7435796 | Antibodies which bind B7RP1 Novel polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed. The polypeptides, or agonists and antagonists ... | 10/14/2008 |
| 7431927 | TNFα-neutralizing antibodies The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monocl... | 10/07/2008 |
| 7425619 | FcγRIIB specific antibodies and methods of use thereof The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods ... | 09/16/2008 |
| 7422738 | Combined cancer treatment methods using antibodies to aminophospholipids Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholi... | 09/09/2008 |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7399468 | Diagnostic and therapeutic use of antibodies against the urokinase receptor The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high ... | 07/15/2008 |
| 7390489 | Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody The present invention relates to a monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes, a hybridoma cell producing the monoclonal antibody, a test kit comprising the monoclonal antibody, and a method for detecting Listeria... | 06/24/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7384633 | Human type antihuman IgE receptor antibody and fragment An antibody or an antibody fragment is provided that is efficacious for treating allergic diseases in which IgE is involved. A human antibody and a fragment thereof to a receptor (FcεRI) having high affinity to Fc portion of IgE was obtained using phage antibody di... | 06/10/2008 |
| 7381802 | Human antibodies that specifically recognize the toxin Cn2 from scorpion venom The present invention is directed to recombinant human antibodies specific for Cn2 toxin from C. noxius scorpion venom. The antibodies are able to recognize the toxin and preferably neutralize it as well as the whole venom of C. noxius scorpion. This i... | 06/03/2008 |
| 7371809 | Pharmacologically active antiviral peptides This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, includin... | 05/13/2008 |
| 7364736 | Antibodies to OPGL Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using an... | 04/29/2008 |
| 7354579 | Method of treating cancer with a VEGF antagonist and an anti-proliferative agent Methods of treating cancer and/or reducing or inhibiting tumor growth in a subject in need thereof, comprising administering pharmaceutical composition comprising a vascular endothelial cell growth factor (VEGF) antagonist, such as a VEGF trap, an anti-proliferative... | 04/08/2008 |
| 7354762 | Method for producing CE7-specific redirected immune cells Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such ... | 04/08/2008 |
| 7351583 | Antibodies to G protein-coupled receptor A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein are described. PHOR-1 is a G protein-coupled receptor with homology to receptors involved in olfaction. PHOR-1 in normal human tissues is restricted ... | 04/01/2008 |
| 7323171 | Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage... | 01/29/2008 |
| 7320789 | Antibody inhibitors of GDF-8 and uses thereof The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative d... | 01/22/2008 |
| 7318921 | Therapeutic compositions that alter the immune response The invention is therapeutic methods and compositions that alter the immunogenicity of the host. ... | 01/15/2008 |
| 7314619 | Inducing apoptosis using anti-Apo-2 antibodies Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided. ... | 01/01/2008 |
| 7314621 | Cytidine deaminase Antibodies that specifically bind to AID (Activation-Induced cytidine Deaminase) proteins, compositions comprising said antibodies, and cells producing said antibodies, are described. The AID proteins are structurally related to APOBEC-1,l an RNA editing enzyme, and... | 01/01/2008 |
| 7297336 | Factor IXa specific antibodies displaying factor VIIIa like activity Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating patients afflicted with blood coagulation with such ligands, and a nu... | 11/20/2007 |
| 7297335 | Immunotoxins directed against CD33 related surface antigens The present invention provides novel immunotoxins and methods of treating neoplastic diseases. These immunotoxins are comprised of a conjugation of an antigen binding region exhibiting binding specificity for the CD33 protein and a cell growth modulator. The immunot... | 11/20/2007 |
| 7291334 | Antibodies to novel proteins in enteroaggregative (EAEC) useful for diagnosis and therapy of EAEC infections Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, an... | 11/06/2007 |
| 7282203 | Use of NOTCH pathway interfering agents for treatment of plasma cell disorders The present invention provides a method for reducing the severity of, or treatment of, plasma cell disorders. The method comprises the step of administering to an individual afflicted with a plasma cell disorder, a composition comprising an antibody directed to the ... | 10/16/2007 |
| 7282567 | Monoclonal antibody hPAM4 This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope o... | 10/16/2007 |
| 7276240 | Antibodies to novel proteins in enteroaggregative (EAEC) useful for diagnosis and therapy of EAEC infections Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, an... | 10/02/2007 |
| 7273924 | Antibodies to the ED-B domain of fibronectin, their construction and uses A specific binding member is specific for and binds directly to the ED—B oncofoetal domain of fibronectin (FN). ... | 09/25/2007 |
